
-
Peruvian cardinal accused of abuse challenges late pope's sanction
-
Trans women barred from women's football by English, Scottish FAs
-
Oil prices drop, stocks diverge amid economic growth fears
-
Israel brings fire near Jerusalem 'under control', reopens roads
-
Lopetegui appointed coach of Qatar
-
UK counter-terrorism unit probes rappers Kneecap but music stars back band
-
Yamal heroics preserve Barca Champions League final dream
-
2026 T20 World Cup 'biggest women's cricket event in England' - ECB
-
Bangladesh begins three days of mass political rallies
-
Children learn emergency drills as Kashmir tensions rise
-
Millions of children to suffer from Trump aid cuts
-
Veteran Wallaby Beale set for long-awaited injury return
-
Syria's Druze take up arms to defend their town against Islamists
-
Tesla sales plunge further in France, down 59% in April
-
US calls on India and Pakistan to 'de-escalate'
-
Israel reopens key roads as firefighters battle blaze
-
Europe far-right surge masks divisions
-
James will mull NBA future after Lakers playoff exit
-
Ukraine's chief rabbi sings plea to Trump to side with Kyiv
-
Australian mushroom meal victim 'hunched' in pain, court hears
-
Lakers dumped out of playoffs by Wolves, Rockets rout Warriors
-
Booming tourism and climate change threaten Albania's coast
-
US reaching out to China for tariff talks: Beijing state media
-
Tariffs prompt Bank of Japan to lower growth forecasts
-
Kiss faces little time to set Wallabies on path to home World Cup glory
-
Serbian students, unions join forces for anti-corruption protest
-
Slow and easily beaten -- Messi's Miami project risks global embarrassment
-
Fan in hospital after falling to field at Pirates game
-
Nuclear power sparks Australian election battle
-
Tokyo stocks rise as BoJ holds rates steady
-
Bank of Japan holds rates, lowers growth forecasts
-
'Sleeping giants' Bordeaux-Begles awaken before Champions Cup semis
-
Napoli eye Scudetto as Inter hope for post-Barca bounce-back
-
Germany's 'absolutely insane' second tier rivalling Europe's best
-
PSG minds on Arsenal return as French clubs scrap for Champions League places
-
UK WWII veteran remembers joy of war's end, 80 years on
-
Myanmar junta lets post-quake truce expire
-
Rockets romp past Warriors to extend NBA playoff series
-
Messi, Inter Miami CONCACAF Cup dream over as Vancouver advance
-
UN body warns over Trump's deep-sea mining order
-
UK local elections test big two parties
-
US judge says Apple defied order in App Store case
-
Seventeen years later, Brood XIV cicadas emerge in US
-
Scorching 1,500m return for Olympic great Ledecky in Florida
-
Israel's Netanyahu warns wildfires could reach Jerusalem
-
Istanbul lockdown aims to prevent May Day marches
-
ReelTime's (RI) Revolutionary Music Generator Now Available to the Public Allowing Commercial Audio Production Capabilities in Most Languages to the RI Community
-
Tradable Bits Launches High-Performance Data Reporting Tool Octane for Live Event Organizations
-
Pivotree Announces Divestiture of Warehouse Management Assets to Tecsys
-
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

The scientist rewriting DNA, and the future of medicine
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.
"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.
- Correcting the code -
DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.
Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.
It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.
"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.
That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.
Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.
These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.
In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.
While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.
"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.
- Cystic fibrosis hope -
Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.
About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.
To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.
If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.
Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."
Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.
Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.
"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."
This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).
"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."
D.Moore--AMWN